Market Overview

Data From an Investigator-Initiated Phase 2 Study of NewLink Genetics' HyperAcute(R) Melanoma Immunotherapy Published in 2012 ASCO Annual Meeting Abstracts

NewLink Genetics Corporation (Nasdaq: NLNK) today announced results from a Phase 2 investigator-initiated study of NewLink's HyperAcute® Melanoma immunotherapy product candidate in combination with pegylated interferon (Sylatron, Merck). The data were published in an abstract (No: e19008) at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting being held in Chicago, IL.

This is in advance of presentations scheduled for Monday, June 4th at ASCO regarding NewLink's HyperAcute Pancreas (algenpantucel-L) and HyperAcute Lung (tergenpumatucel-L) immunotherapy product candidates and IDO pathway inhibitor, NLG8189 (D-1mT) product candidate.

Posted-In: News FDA

 

Related Articles (NLNK)

Around the Web, We're Loving...

Get Benzinga's Newsletters